Aslan Pharmaceuticals Limited (ASLN) Return on Assets ROA from the fourth quarter of 2023 to fourth quarter of 2022 and for the year 2023, Average High and Low, Fundamental Ratios from Dec 31 2023 to Dec 31 2022 - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Aslan Pharmaceuticals Limited  (NASDAQ: ASLN)


Aslan Pharmaceuticals Limited's ROA from the fourth quarter of 2023 to the fourth quarter of 2022 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics


What is Aslan Pharmaceuticals Limited's ROA in the fourth quarter of 2023?
Aslan Pharmaceuticals Limited recorded a cumulative net loss of $-44 million during 12 months ending in the fourth quarter of 2023, resulting in a negative return on assets (ROA) of -135.84%.

However, within the Healthcare sector 1068 other companies had a higher return on assets. While return on assets, the total ranking has deteriorated compared to the third quarter of 2023 from to 5684.

What is ROA?


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Assets (Dec 31 2023)
IV. Quarter		 0
III. Quarter		 0
II. Quarter		 0
I. Quarter		 (Dec 31 2022)
IV. Quarter
Y / Y Total Assets Change -59.75 % -59.75 % -14.48 % -59.75 % -35.27 %
Y / Y Net Income Change - - - - -
Net Income (TTM) in million -44 -51 -51 -51 -51
Return On Assets (TTM) -135.84 % -123.24 % -101.08 % -96.55 % -82.4 %
ASLN's Total Ranking # 5684 # # # # 5848
Total Assets (TTM) in million 25 25 56 25 61
Seq. Total Assets Change 0.01 % -56.28 % 128.75 % -59.75 % 0.01 %
Seq. Net Income Change - - - - -

ASLN's 5 Years Annual ROA >> Back to ASLN Management Effectiveness >> Compare ASLN ROA to its Competitors


Return On Assets Company Ranking
Within: No.
Industry # 519
Sector # 1069
Overall # 5558

Return On Assets Statistics
High Average Low
-33.42 %
-120.81 %
-201.57 %
(Dec 31 2021)   (Dec 31 2019)



  News about Aslan Pharmaceuticals Limited Return on Assets ROA

ASLAN Pharmaceuticals Faces Nasdaq Delisting After Failing to Meet Listing Requirements, Future Remains Uncertain


On July 9, 2024, ASLAN Pharmaceuticals received notification from the staff of the Listing Qualifications Department at Nasdaq regarding its non-compliance with the $1.00 bid price and $2.5 million stockholders equity requirements, as outlined in Nasdaq Listing Rules 5550(a)(2) and 5550(b)(1).
After careful consideration by the company s board of directors, ASLAN Pharmaceuticals has chosen not to request a hearing before the Nasdaq Hearings Panel, effectively accepting the delisting determination. This decision implies that ASLAN will no longer be traded on the Nasdaq exchange.



Financial Statements
Aslan Pharmaceuticals Limited's Assets $ 25 million ASLN's Balance sheet
Aslan Pharmaceuticals Limited's Income $ -44 million Quarterly ASLN's Income Statement
ASLN's Income by Division See ASLN's Income by Division



Annual Return On Assets (Dec 31 2023)
FY 2023		 (Dec 31 2022)
FY 2022		 (Dec 31 2021)
FY 2021		 (Dec 31 2020)
FY 2020		 (Dec 31 2019)
FY 2019
Y / Y Total Assets Change -59.75 % -35.27 % 484.04 % -30.57 % -69.11 %
Total Assets in million 25 61 95 16 23
Y / Y Net Income Change - - - - -
Net Income in million -44 -51 -32 -17 -47
Annual Return On Assets -179.55 % -83.97 % -33.42 % -104.86 % -201.88 %

ASLN's 5 Years Annual ROA >> Back to ASLN Management Effectiveness >> Compare ASLN ROA to its Competitors



More Return On Assets Ratios
ASLN's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
ASLN's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for ASLN's Competitors
Subscribers only: Roa for Aslan Pharmaceuticals Limited's Suppliers
Subscribers only: Return On Assets for ASLN's Customers

You may also want to know
ASLN's Roi ASLN's Inventory Turnover Ratio ASLN's Growth Rates ASLN's Dividend Comparisons
ASLN's Profitability Ratios ASLN's Asset Turnover Ratio ASLN's Dividend Growth
ASLN's Roe ASLN's Valuation Ratios ASLN's Financial Strength Ratios ASLN's Dividend Payout Ratio



Companies with similar Return On Assets at Dec 31 2023, within Healthcare Sector ROA

Date modified: 2026-09-18T13:11:05+00:00


Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.